Course Outcome:
CO1: Describe the fundamental concepts of immune cell engineering and the technologies used to modify immune cells for therapeutic purposes.
CO2: Explain the structure, function, and mechanism of action of CAR-T cells and analyze how design elements influence therapeutic outcomes.
CO3: Demonstrate an understanding of CAR-T manufacturing processes, GMP standards, and quality control measures necessary for clinical application.
CO4: Evaluate clinical applications, trial designs, and safety concerns associated with CAR-T therapies in hematologic and solid tumors.
CO5: Analyze emerging strategies in immune cell engineering, including advanced CAR constructs and alternative immune cell therapies.
CO6: Discuss regulatory frameworks, ethical issues, and translational challenges involved in the commercialization and global accessibility of CAR-T therapies.
Program outcome
PO1: Bioscience Knowledge
PO2: Problem Analysis
PO3: Design/Development of Solutions
PO4: Conduct Investigations of complex problems
PO5: Modern tools usage
PO6: Bioscientist and Society
PO7: Environment and Sustainability
PO8: Ethics
PO9: Individual & Team work
PO10: Communication
PO11: Project management & Finance
PO12: Lifelong learning
0 – No affinity; 1 – low affinity; 2 – Medium affinity; 3 – High affinity
CO |
PO1 |
PO2 |
PO3 |
PO4 |
PO5 |
PO6 |
PO7 |
PO8 |
PO9 |
PO10 |
PO11 |
PO12 |
CO1 |
3 |
3 |
3 |
3 |
3 |
2 |
1 |
2 |
1 |
2 |
2 |
3 |
CO2 |
3 |
3 |
3 |
3 |
3 |
2 |
1 |
2 |
1 |
2 |
2 |
3 |
CO3 |
3 |
3 |
3 |
3 |
3 |
3 |
1 |
2 |
1 |
2 |
3 |
3 |
CO4 |
3 |
3 |
2 |
3 |
2 |
3 |
1 |
2 |
2 |
2 |
2 |
3 |
CO5 |
3 |
3 |
3 |
3 |
3 |
2 |
1 |
2 |
2 |
2 |
2 |
3 |
CO6 |
3 |
2 |
2 |
2 |
2 |
3 |
2 |
3 |
2 |
2 |
2 |
3 |
Program-specific outcome
PSO 1 – Emerging technologies in cell therapy
PSO 2 – Biomolecules in Medicine
PSO 3 – Molecular dysregulation in diseases
PSO 4 – Molecular technology in diagnosis and therapy
PSO 5 – Applying lab discoveries to clinical practice
PSO 6 – Advanced techniques in cell culture, gene editing, and bioprocessing
PSO 7 – Statistical methods to interpret and validate diagnostic results
PSO 8 – Integrate cell therapy into personalized medicine
PSO 9 – GMP and regulatory practices in cell therapy production
PSO 10 – Bioinformatics and biological data use
0 – No affinity; 1 – low affinity; 2 – Medium affinity; 3 – High affinity
CO |
PSO1 |
PSO2 |
PSO3 |
PSO4 |
PSO5 |
PSO6 |
PSO7 |
PSO8 |
PSO9 |
PSO10 |
CO1 |
3 |
2 |
2 |
2 |
2 |
3 |
1 |
2 |
2 |
2 |
CO2 |
3 |
2 |
2 |
3 |
3 |
3 |
1 |
2 |
2 |
2 |
CO3 |
3 |
1 |
2 |
2 |
3 |
3 |
2 |
2 |
3 |
2 |
CO4 |
3 |
2 |
3 |
2 |
3 |
2 |
2 |
2 |
2 |
2 |
CO5 |
3 |
2 |
2 |
3 |
3 |
3 |
2 |
3 |
2 |
2 |
CO6 |
3 |
1 |
1 |
2 |
2 |
2 |
1 |
2 |
3 |
2 |